suPARnostic® in acute care
suPARnostic® by ViroGatesEmpowering clinical decisions
suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better-informed decisions backed by reliable biological data across diseases.
suPAR (soluble urokinase plasminogen activator receptor) shows how active a patient’s immune system is, regardless of the underlying disease. Levels rise as a condition worsens, and higher levels mean greater risk of disease progression and mortality.
suPAR gives clinicians an early, objective signal, alongside clinical findings and other lab tests, to identify who can be discharged safely and who needs closer monitoring or admission.
Used in triage, suPAR is linked to faster, safer discharges, fewer unnecessary admissions, and shorter hospital stays, helping Emergency Departments put resources where they’re needed most.
How to interpret suPAR results
suPAR level < 4 ng/mL
Supports patient discharge
suPAR level > 6 ng/mL
Supports patient hospitalisation
suPAR is measured from a single blood sample. The suPARnostic® TurbiLatex assay run time is ~20 minutes, fitting directly into existing central-laboratory workflows (turnaround time may vary by suPARnostic® product).
suPAR results should always be interpreted together with the patient’s clinical history and other diagnostic test results, not as a stand-alone decision tool.
What suPAR delivers in practice
Improved patient care
Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient.
Reduced healthcare costs
Shorter hospital stays can meaningfully lower the cost of each admission, easing pressure on stretched hospital budgets.
Empowering clinical staff
Get more information to make more confident decisions to potentially reduce uncertainty.
How suPARnostic® works at the emergency department
Step 1
A patient is admitted to the emergency department for observation
Step 2
The patient’s blood sample is drawn
Step 3
The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow
Step 4
The physician gets the result and makes a triage decision
The evidence
suPAR is a significant, independent predictor of mortality in acute medical and Emergency Department patients, confirmed across multiple cohorts:
• In the validation cohort of 1,747 acute medical patients underlying the suPARnostic® TurbiLatex cut-offs, suPAR <4.0 ng/mL carried a 99.0% negative predictive value and 94.2% sensitivity for 90-day mortality; suPAR >6.0 ng/mL carried a 20.1% positive predictive value and 78.7% specificity (Seppälä et al., preprint).
• In patients with confirmed COVID-19, suPAR also stratifies the risk of respiratory failure requiring mechanical ventilation: in a validation cohort of 100 patients, suPAR <4.0 ng/mL carried
a 100% negative predictive value, while levels >6.0 ng/mL carried a 10.2% positive predictive value (Mikkeli Central Hospital cohort).
• A randomized controlled trial in more than 16,000 acute medical patients (TRIAGE III) showed suPAR-guided triage led to significantly more discharges within 24 hours and a 6.5-hour shorter average length of stay — with no increase in mortality (Schultz et al.).
suPAR’s prognostic value holds even after adjusting for age, sex, comorbidity burden and CRP, and correlates with risk across age groups and comorbidity levels — including in patients presenting with few visible clinical signs (Haupt et al. 2012; Rasmussen et al., Crit Care Med 2018).
“It is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”
Juan González del Castillo,
Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019
suPAR independently predicts mortality in emergency department patients
| All | suPAR ≤ 4 ng/mL | suPAR > 4 and < 6 ng/mL | suPAR ≥ 6 ng/ml | P Value | |
|---|---|---|---|---|---|
| N | 1747 | 804 | 514 | 429 | |
| Discharge < 24 H N | 785 | 462 | 215 | 108 | < 0.001 |
| 30 Day pre-admitted N | 379 | 131 | 121 | 127 | < 0.001 |
| Readmission 30 Days N | 368 | 153 | 114 | 101 | 0,14 |
| Mortality 7 Days N | 34 | 3 | 9 | 22 | < 0.001 |
| Mortality 30 Days N | 81 | 6 | 25 | 50 | < 0.001 |
| Mortality 90 Days N | 138 | 8 | 43 | 87 | < 0.001 |
